Gyre Therapeutics Revenue
Biotechnology Research • 
San Diego, California, United States • 11-20 Employees
Gyre Therapeutics revenue & valuation
| Annual revenue | $1,112,215 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,600,000 |
| Total funding | No funding |
Key Contacts at Gyre Therapeutics
Renate Parry
Independent Director & Compensation Committee Chair
Han Ying
Chief Executive Officer
Company overview
| Headquarters | 12770 High Bluff Drive, Suite 150, San Diego , CA 92130, US |
| Website | |
| NAICS | 541714 |
| Employees | 11-20 |
| Socials |
Gyre Therapeutics Email Formats
Gyre Therapeutics uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@gyretx.com), used 54.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@gyretx.com | 54.5% |
{first initial}.{last name} | j.doe@gyretx.com | 45.5% |
About Gyre Therapeutics
Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE) is a commercial-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases. Gyre is headquartered in San Diego, CA, with a primary focus on the development and commercialization of anti-fibrotic therapeutics for a variety of chronic organ diseases. Gyre has successfully advanced ETUARY® from research to commercialization. Its sales are re-invested to fund Gyre’s clinical development pipeline. Gyre's lead compound F351 is a derivative of ETUARY® (Pirfenidone) and has obtained breakthrough therapy designation status for chronic HBV-associated liver fibrosis. A phase 3 confirmative clinical study is being conducted based on the phase 2 POC clinical data. A F351 phase I study has been completed in the US. An IND for a phase 2 clinical study will be filed for the treatment of NASH-associated fibrosis in the U.S. in 2024. F351 effectively suppresses chronic inflammation pathways, including the TGFbeta signaling pathway. As a result, it presents a promising therapeutic strategy as a single agent and opportunity for combination therapy with metabolic inhibitors in treating organ fibrotic diseases. Gyre is also advancing a diverse pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Gyre Therapeutics has 7 employees across 5 departments.
Departments
Number of employees
Funding Data
Gyre Therapeutics has never raised funding before.
Gyre Therapeutics Tech Stack
Discover the technologies and tools that power Gyre Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Security
Miscellaneous
Maps
JavaScript libraries
Font scripts
JavaScript libraries
Programming languages
Blogs
UI frameworks
Hosting
Reverse proxies
Denmark
Malta
Viet Nam
Hungary
AustraliaFrequently asked questions
4.8
40,000 users
